Partner
Peter De Ryck
Corporate and M&A
Private Equity & Venture Capital
Insolvency and Restructuring
peter.deryck@lydian.be
Lydian advised Pathos on its acquisition of a majority stake in DeuterOncology
We are pleased to have assisted Pathos in taking a majority stake in DeuterOncology NV, a Belgium-based company active in the development of innovative oncology therapies.
Pathos is a biopharma company focused on precision oncology, using advanced AI and large‑scale patient data to design smarter clinical trials and improve the success of developing new cancer therapies. This transaction marks an important step in supporting the continued growth of DeuterOncology and highlights the ongoing momentum in the life sciences sector.
Lydian advised Pathos on all Belgian aspects of the transaction.
The Lydian team was composed of Peter De Ryck (Partner), Louise Berrier (Senior Associate) and Clément Defechereux (Associate).
For more information about this transaction or our legal services, feel free to reach out to our team.
Authors
-
Download VCARD
-
-
